306 related articles for article (PubMed ID: 33843223)
1. GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.
Carullo G; Mazzotta S; Vega-Holm M; Iglesias-Guerra F; Vega-Pérez JM; Aiello F; Brizzi A
J Med Chem; 2021 Apr; 64(8):4312-4332. PubMed ID: 33843223
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists.
Zhang X; Cai C; Winters M; Wells M; Wall M; Lanter J; Sui Z; Ma J; Novack A; Nashashibi I; Wang Y; Yan W; Suckow A; Hua H; Bell A; Haug P; Clapper W; Jenkinson C; Gunnet J; Leonard J; Murray WV
Bioorg Med Chem Lett; 2017 Aug; 27(15):3272-3278. PubMed ID: 28642104
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Winters MP; Sui Z; Wall M; Wang Y; Gunnet J; Leonard J; Hua H; Yan W; Suckow A; Bell A; Clapper W; Jenkinson C; Haug P; Koudriakova T; Huebert N; Murray WV
Bioorg Med Chem Lett; 2018 Mar; 28(5):841-846. PubMed ID: 29456108
[TBL] [Abstract][Full Text] [Related]
4. Biological characteristics and agonists of GPR120 (FFAR4) receptor: the present status of research.
Li A; Li Y; Du L
Future Med Chem; 2015; 7(11):1457-68. PubMed ID: 26230883
[TBL] [Abstract][Full Text] [Related]
5. Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes.
Ji G; Guo Q; Xue Q; Kong R; Wang S; Lei K; Liu R; Wang X
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833999
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel and Selective G-Protein Coupled Receptor 120 (GPR120) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Wang X; Li X; Wei S; Wang M; Xu Y; Hu W; Gao Z; Liu R; Wang S; Ji G
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558150
[TBL] [Abstract][Full Text] [Related]
7. Diphenyl Ether Derivatives as Novel GPR120 Agonists for the Treatment of Type 2 Diabetes Mellitus.
Wang X; Wei S; Wang M; Xu Y; Hu W; Niu M; Wang S; Lei K; Ji L; Liu R; Ji G
Chem Biodivers; 2023 Jan; 20(1):e202200814. PubMed ID: 36471492
[TBL] [Abstract][Full Text] [Related]
8. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a potent and selective GPR120 agonist.
Shimpukade B; Hudson BD; Hovgaard CK; Milligan G; Ulven T
J Med Chem; 2012 May; 55(9):4511-5. PubMed ID: 22519963
[TBL] [Abstract][Full Text] [Related]
10. Free Fatty Acid Receptors (FFARs): Emerging Therapeutic Targets for the Management of Diabetes Mellitus.
Loona DPS; Das B; Kaur R; Kumar R; Yadav AK
Curr Med Chem; 2023; 30(30):3404-3440. PubMed ID: 36173072
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
[TBL] [Abstract][Full Text] [Related]
12. GPR120 agonism as a countermeasure against metabolic diseases.
Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
Drug Discov Today; 2014 May; 19(5):670-9. PubMed ID: 24315954
[TBL] [Abstract][Full Text] [Related]
13. Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonist.
Sparks SM; Aquino C; Banker P; Collins JL; Cowan D; Diaz C; Dock ST; Hertzog DL; Liang X; Swiger ED; Yuen J; Chen G; Jayawickreme C; Moncol D; Nystrom C; Rash V; Rimele T; Roller S; Ross S
Bioorg Med Chem Lett; 2017 Mar; 27(5):1278-1283. PubMed ID: 28148462
[TBL] [Abstract][Full Text] [Related]
14. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice.
Oh DY; Walenta E; Akiyama TE; Lagakos WS; Lackey D; Pessentheiner AR; Sasik R; Hah N; Chi TJ; Cox JM; Powels MA; Di Salvo J; Sinz C; Watkins SM; Armando AM; Chung H; Evans RM; Quehenberger O; McNelis J; Bogner-Strauss JG; Olefsky JM
Nat Med; 2014 Aug; 20(8):942-7. PubMed ID: 24997608
[TBL] [Abstract][Full Text] [Related]
15. Potential roles of GPR120 and its agonists in the management of diabetes.
Zhang D; Leung PS
Drug Des Devel Ther; 2014; 8():1013-27. PubMed ID: 25114508
[TBL] [Abstract][Full Text] [Related]
16. Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects.
Lombardo M; Bender K; London C; Plotkin MA; Kirkland M; Mane J; Pachanski M; Geissler W; Cummings J; Habulihaz B; Akiyama TE; Di Salvo J; Madeira M; Pols J; Powles MA; Finley MF; Johnson E; Roussel T; Uebele VN; Crespo A; Leung D; Alleyne C; Trusca D; Lei Y; Howard AD; Ujjainwalla F; Tata JR; Sinz CJ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5724-5728. PubMed ID: 27815121
[TBL] [Abstract][Full Text] [Related]
17. Identification and target-pathway deconvolution of FFA4 agonists with anti-diabetic activity from Arnebia euchroma (Royle) Johnst.
Xu F; Wang P; Zhang X; Hou T; Qu L; Wang C; Wang J; Liu Y; Liang X
Pharmacol Res; 2021 Jan; 163():105173. PubMed ID: 33027715
[TBL] [Abstract][Full Text] [Related]
18. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus.
Defossa E; Wagner M
Bioorg Med Chem Lett; 2014 Jul; 24(14):2991-3000. PubMed ID: 24881568
[TBL] [Abstract][Full Text] [Related]
19. IL-1β and TNFα inhibit GPR120 (FFAR4) and stimulate GPR84 (EX33) and GPR41 (FFAR3) fatty acid receptor expression in human adipocytes: implications for the anti-inflammatory action of n-3 fatty acids.
Muredda L; Kępczyńska MA; Zaibi MS; Alomar SY; Trayhurn P
Arch Physiol Biochem; 2018 May; 124(2):97-108. PubMed ID: 28835131
[TBL] [Abstract][Full Text] [Related]
20. GPR40 carboxylic acid receptor family and diabetes: a new drug target.
Telvekar VN; Kundaikar HS
Curr Drug Targets; 2008 Oct; 9(10):899-910. PubMed ID: 18855625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
